Image may be NSFW.
Clik here to view.
Novocure (NSDQ:NVCR) today touted positive top-line data from its Phase II pilot mesothelioma trial and revealed that it plans to submit a humanitarian device exemption application to the FDA for approval.
The St. Helier, N.J.-based company reported that patients who received treatment with its “Tumor Treating Fields” system plus chemotherapy experienced clinically meaningful improvements in overall survival and progression-free survival compared to historical control data.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure touts top-line data from Ph2 mesothelioma trial appeared first on MassDevice.
